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public databases information and clinical expert panel. The target population was
a birth cohort in São Paulo followed for 5 years (598,474). The vaccination coverage
rate was 90%, considering a four-dose schedule for 10-valent and tree-dose sched-
ule for PCV13 as suggested by international guides. São Paulo costs and disease
data was obtained from national official databases. A mandatory discounted price
to the government, calculated by the ex-factory price minus 24.38% was considered
to PCV13 and 10-valent. Costs and benefits were discounted at 5% annually. Out-
comes were expressed as life years gained(LYG), deaths and number of disease
cases avoided. Only the direct effect of vaccination and direct medical costs were
considered. RESULTS: The analysis showed higher clinical benefits and lower
costs for PCV13 prophylaxis; reduction of 7 deaths, 488 LYG and 17 cases of
disease (sepsis and meningitis) and savings of BRL70,097,844(USD43,909,950) in
5 years. The total costs with events and vaccines were
BRL113,902,160(USD72,576,883) and BRL137,914,893(USD87,877,465), respec-
tively, for PCV13; and BRL113,999,789(USD71,410,542) and
BRL207,915,109(USD130,239,983) for 10-valent. CONCLUSIONS: This study dem-
onstrated that incorporating PCV13 in pediatric immunization routine results in
reduction on mortality and morbidity with lower expected cost for São Paulo state
healthcare system, showing the dominance of PCV13 regarding 10-valent.
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OBJECTIVES: Invasive aspergilosis (IA) is a mycotic disease produce by Aspergillus
sp and represents the second leading cause of invasive fungal infections. The mor-
tality rate is about 50%. The aim of this study was to assess the cost-effectiveness
(CE) of voriconazol, anfotericine B and caspofungin as first line treatments for IA
adult patients in Panama, from the healthcare payer’s perspective. METHODS: A
decision-tree model was used to compare costs and effectiveness of anfotericine B
(comparator), caspofungin and voriconazol for a cohort of patients with IA. Effec-
tiveness measures were: clinical success rates, mortality rates, intensive care unit
(ICU) length of stay (LOS), hospital ward LOS and overall costs. Effectiveness and
epidemiologic data were collected from published literature. Local costs (2011 US$)
were obtained from Panama=s Social Security and Hospital Oncológico Nacional
official databases. The model used a 12-week time horizon and only direct medical
costs were considered. Monte Carlo probabilistic sensitivity analysis (PSA) was
constructed. RESULTS: Results showed voriconazol as the most effective and least
expensive option for IA. Clinical success rate was higher with voriconazol (56.6%)
compared with anfotericine B (36.4%) and caspofungin (34.2%). Mortality rates
were: 34.1% with voriconazol, 50.9% with anfotericine B and 44.7% with caspofun-
gin. Average ICU LOSs was 7.59 days with voriconazol and 9.94 and 9.81 days with
anfotericine B and caspofungin, respectively. Voriconazol also obtained the short-
est ward LOS (15.96 days). Overall medical costs were $13,100 with voriconazol,
$17,347 with anfotericine B and $13,716 with caspofungin. CE analyses showed
voriconazol as the dominant strategy. Acceptability curves showed that voricona-
zol would be cost-effective within 3 GDP per capita threshold. PSA outcomes
support the robustness of these findings. CONCLUSIONS: This is the first CE study
for IA developed in Panamá. Voriconazol resulted as the cost-saving option for
treating IA patients in the Panamanian clinical context.
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OBJECTIVES: The aim of this study is to analyze the cost-effectiveness over 6-year
duration of first line telbivudine and lamivudine treatment in HBeAg-positive
chronic hepatitis B patients with low viral load at baseline in line with the Turkish
reimbursement guideline for oral CHB therapies. METHODS: Using a decision an-
alytical model, cost-effectiveness of telbivudine was evaluated versus lamivudine
in first-line use for HBeAg-positive patients with baseline HBV DNA levels9 log10
copies/mL in Turkish healthcare setting from National Payer’s perspective in ac-
cordance with the local reimbursement guideline for oral CHB treatments based on
roadmap concept. Primary measure of effectiveness was undetectable HBV DNA
level by polymerase chain reaction (PCR) assay at model duration, while costs
included only cost of oral CHB drugs incurred by the Payer. Probabilities of PCR
negativity and resistance rates used in the model are derived from telbivudine’s
head-to-head study versus lamivudine subgroup analyses outcomes for week 24
and 104; and from respective pivotal clinical studies for second line treatments.
RESULTS: In the CE model, total oral CHB treatment cost per HBeAg-positive pa-
tient treated with lamivudine and telbivudine arm over 6 years was estimated to be
12,873€ and 11,435€ respectively. Percentage of patients remaining on lamivudine
at model duration was 23%, while 50% on telbivudine. The average cost-effective-
ness ratio, cost per successfully treated HBeAg-positive patient at year 6, was cal-
culated as 15,362€ for the lamivudine arm and 13,053€ for the telbivudine arm
(difference is 2,309€), and the incremental cost-effectiveness ratio was -37,859€.
CONCLUSIONS: First line CHB treatment with telbivudine in HBeAg-positive pa-
tients has been demonstrated as a dominant cost-effective option than lamivudine
in the Turkish healthcare setting. Although telbivudine has higher reimbursement
price, it has been offset by superior efficacy compared to lamivudine in positive
patients with baseline serum HBV DNA levels9 log10 copies/mL and less need for
more costly second line treatments.
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OBJECTIVES: To estimate the cost of virologic response at week 48 of treatment
with etravirine (ETV), raltegravir (RAL) and maraviroc (MAV) for multi-experienced
patients with 2 or more active drugs in the optimized background therapy (OBT) in
the Brazilian National AIDS Program. METHODS: Treatment regimens of ETV and
RAL were defined by the Brazilian national guidelines. Regimens with MAV were
based in the same principles, although the drug is not yet reimbursed. Patients not
achieving virologic response followed onto subsequent rescue treatments, defined
by the guidelines. Re-treatment was not allowed. Treatment costs included cost of
medication as published on the government website. The cost of MAV was defined
by law. The number of multi-experienced patients receiving treatment was based
on the dispensed capsules of RAL in the last 48 weeks. Virologic response was
gathered from the phase III clinical trials of ETV, MAR and RAL, at week 48 for
patients with two active drugs in the OBT defined by phenotypic susceptibility.
RESULTS: The average cost of treatment at week 48 for multi-experienced patients
with at least 2 active drugs in the OBT was R$ 27,243.14 with ETV, compared with R$
27,702.91 with RAL, and R$ 31,220.72 with MAR. Given 5,627 multi-experienced
patients received treatment, 862 patients failed with MAV, 544 failed treatment
with RAL compared to 337 failed patients with ETV. For one third of the cohort
(1.875), the total cost of treatment was R$ 58,565,276 for MAV, R$ 51,966,391 for RAL,
and R$ 51,103,946 for ETV. CONCLUSIONS: Despite similar treatment costs, treat-
ment with ETV compared to RAL and MAV is a more economic option for the
treatment of multi-experienced patients with at least two active drugs in the OBT.
At week 48, treatment with RAL and MAV was on average 2% and 15% more expen-
sive compared to ETV, respectively.
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OBJECTIVES: To develop a cost-effectiveness analysis of a multidisciplinary sup-
port program (MSP) versus the conventional approach in the Hepatitis C (HC)
treatment. METHODS: A total of 278 mono-infected naive HC patients were in-
cluded: 131 in the MSP group and 147 patients were conventionally controlled
(control group). All patients were treated with Peg-IFN-alfa-2a/ribavirin. The MSP
team not only included hepatologists and nurses, but also, pharmacists, psychol-
ogists and assistants. Standard patient education, open and flexible visits sched-
uling, continued psychiatric evaluation and active medication control were carried
out in the MSP. Treatment adherence, sustained virological response (SVR), and
health resources use were evaluated. A Markov model for a lifetime horizon with
seven health states and from the Spanish NHS perspective was developed. Tran-
sition probabilities and health states utilities were obtained from published liter-
ature. Costs were obtained from the Catalogue of Medicinal Products and from
Spanish studies and databases (€-2010). 3.5% annual discount for costs and out-
comes was applied. RESULTS: In the MSP group treatment compliance was higher
than in the control group (94.6% vs 78.9%, p0.0001). SVR was higher in the MSP
group than in controls for all genotypes (77.1% vs. 61.9%, p0.006), G-1/4 (67.7% vs
48.9%, p0.02), and G-2/3 (87.7% vs. 81.4%, NS). For all genotypes, the cost per
patient (including cost of drugs, health professionals and disease long-term com-
plications) was €13,319 in MSP group and €16,184 in control group, furthermore,
MSP group resulted more QALYs than controls (16.317 vs. 15.814), being MSP dom-
inant (more effective, with lower costs) compared with the conventional approach.
The MSP program was also dominant in G-1/4 patients (saving €2476, increasing
0.622 QALYs/patient) and G-2/3 (saving €1417, gaining 0.208 QALYs/patient). Re-
sults were stable for 95% CI of drug doses. CONCLUSIONS: HC treatment with
Peg-IFN-alfa-2a/ribavirin in a MSP improves the compliance and is a cost-effective
strategy compared with the conventional approach.
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OBJECTIVES: In 2010, there were more than 1500 illness related to Streptococcus
pneumonia infections in pediatric population under 2 years old in Panamá. Cur-
rently, in Panamá, Prevenar 7 is the anti-pneumococcal vaccine (PCV) used. The
aim of this study was to estimate the cost-effectiveness and cost-utility of immu-
nization strategies based on pneumococcal conjugated vaccines (PCVs) in Panamá,
from an institutional perspective. METHODS: A decision tree steady state model
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was used to assess the population level public health and economic impact of
infant anti-pneumococcal vaccination. The alternatives compared were: no vacci-
nation (comparator), PCV-7, PCV-10 and PCV-13. The effectiveness measures were:
child illness avoided, life years gained (LYs) and quality-adjusted life years (QALYs)
gained. Effectiveness and utilities were obtained from literature. Local costs (ex-
pressed in 2011 $US) and epidemiology (data from 2009-2011) were obtained from
Panamá=s official databases. Univariate sensitivity analysis was performed. The
time horizon for total costs was one year and for outcomes was lifetime with a
discount rate of 3%. RESULTS: Results show that immunization is cost-saving
against no-vaccination. PCV-13 gained the highest number of QALYs (305) against
PCV-10 (191) and PCV-7 (168). PCV-13 prevented 629 illnesses and gained 334 LYs.
PCV-10 and PCV-7 prevented 392 and 359 illnesses and gained 208 and 182 LY=s,
respectively. Total costs of illness with PCV-13, PCV-10, PCV-7 and no vaccination
were $622,445, $777,878, $804,978 and $1,005,512, respectively. These results were
robust to variations in herd immunity and impact adjustments of PCV-10
immunogenicity. CONCLUSIONS: This is the first cost-effectiveness study for anti-
pneumococcal immunization in Panamá. Immunization strategies based on 7, 10
and 13-valent PCV=s may be cost-saving interventions compared to no vaccination.
PCV-13 dominates PCV-10 and PCV-7.
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OBJECTIVES: . Pneumococcal bacteremia and pneumonia are priority diseases for
public health in Guatemala since these are among the 10 most frequent causes of
hospitalizations and mortality in children under 4 years old. The aim of this study
was to estimate the cost-effectiveness of immunization strategies based on pneu-
mococcal conjugate vaccines (PCVs) in Guatemala, from an institutional
perspective.METHODS: . A decision tree steady state model was used to assess the
population level public health and economic impact of infant anti-pneumococcal
vaccination. The alternatives compared were: no vaccination (comparator), PCV-10
and PCV-13. The effectiveness measures were: illness avoided life years gained
(LYs) and quality-adjusted life years (QALYs) gained. Effectiveness and utilities
were obtained from literature. Local costs (expressed in 2011 $US) and epidemiol-
ogy (data from 2009-2011) were obtained from Guatemala=s official databases. Uni-
variate sensitivity analysis was performed. The time horizon for total costs was one
year and for outcomes was lifetime with a discount rate of 3%. RESULTS: . Results
show that immunization is cost-saving against no-vaccination. PCV-13 gained
more QALYs (7,569) against PCV-10 (5,824). PCV-13 prevented 5658 illnesses and
gained 8404 LYs, while PCV-10 prevented 4140 illnesses and gained 6465 LYs. Total
costs of illness with PCV-13, PCV-10 and no vaccination were $2,599,952, $3,071,811
and $5,534,657, respectively. These results were robust to variations in herd immu-
nity and impact adjustments of PCV-10 immunogenicity. CONCLUSIONS: . This is
the first cost-effectiveness study for anti-pneumococcal immunization developed
in Guatemala. Immunization strategies based on 10 and 13-valent PCV=s may be
cost-saving interventions. PCV-13 dominates PCV-10.
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OBJECTIVES: Rotavirus gastroenteritis (RVGE) is one of the most frequent diseases
among children aged 5 or younger. A general recommendation for rotavirus vacci-
nation in Germany does not exist so far, leading to a vaccination rate of 30%. This
analysis simulates the cost-effectiveness of a general rotavirus vaccination in Ger-
many using Rotarix™ from the perspective of the statutory health insurance (SHI).
METHODS:An existing Markov model on rotavirus infection in children (published
before) was adapted to the German situation. The model simulates costs and ef-
fects of rotavirus vaccination in a birth cohort of 699,301 children. In the model,
vaccine efficacy rates from international clinical trials were combined with Ger-
man epidemiology and cost data from the SHI perspective for 2011 (including SHI
reimbursed productivity losses of parents). The model assumes a vaccination rate
of 100% and discount rates of 3% for costs and effects. Results were tested for
robustness using sensitivity analyses. RESULTS: A 100% vaccination with Rotar-
ixTM could avoid approximately 156,000 RVGE cases and associated physician vis-
its as well as in-patient hospital stays. From the SHI perspective, this leads to cost
savings of 13.6 Mio € in total. The main factors responsible for these savings are
in-patient hospital stays avoided (64.1 Mio €), SHI reimbursed productivity losses of
parents (19.0 Mio €) and physician visits avoided (5.4 Mio €). On the other hand,
vaccination costs amount to additional 79.4 Mio €. Stability of results was most
sensitive with respect to epidemiological parameters (number of RVGE cases, in-
patient hospital cases) as well as productivity loss. CONCLUSIONS: A general™
vaccination against rotavirus in Germany can avoid severe diarrhea events in chil-
dren aged 5 and younger. Additional vaccination costs for the SHI are more than
outbalanced by cost savings through in-patient hospital stays, SHI reimbursed
productivity loss and physician visits avoided.
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OBJECTIVES: To estimate the cost of virologic failure with the treatment of etra-
virine and raltegravir in multi-experienced patients in the Brazilian National AIDS
Program. METHODS: Treatment regimens of etravirine and raltegravir were de-
fined by the guidelines of the Brazilian National AIDS Program. Upon virologic
failure, subsequent treatments were defined according to the same guidelines con-
sidering new drug combinations not yet used by the patients. Treatment costs
considered the cost of medication as purchased by the Brazilian government and
published on their website. As maraviroc, a rescue treatment, is not yet reimbursed
by the AIDS program, its price was defined by law. To estimate the total cost,
patient numbers were calculated by the number of capsules of raltegravir dis-
pensed in the past 96 weeks, and assumed the same for patients treated with
etravirine. Virologic failure was gathered from the phase III clinical trials of ralte-
gravir and etravirine at week 48 and week 96. RESULTS: The average cost of treat-
ment for multi-failure patients with etravirine was on average R$ 26.692,26 at week
48 of treatment compared to R$ 26.634,15 per patient treated with raltegravir. At
week 96, the average treatment cost per patient was R$ 56.810,59 for raltegravir and
R$ 53.904,30 for etravirine. Given that 3.942 patients received treatment in the
previous 98 weeks, around 1.301 patients will fail treatment with raltegravir and
630 with etravirine. The total cost of treating these patients is R$ 73 million for
raltegravir and R$ 34 million for etravirine. CONCLUSIONS: Despite a similar aver-
age cost at week 48, etravirine treatment is a more economic option for the treat-
ment of multi-failure patients compared to raltegravir, saving up to 50% of treat-
ment costs with virologic failure patients in the Brazilian National AIDS program
over 96 weeks. Virologic failure is therefore an important indicator to avoid subse-
quent treatment costs especially in the long-term.
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OBJECTIVES: The analysis aimed to evaluate the cost-effectiveness of 48-week
therapy with peginterferon alpha-2a (PegIFN-2a) in HBeAg-negative chronic hep-
atitis B (CHB) patients versus 48-week (short-term analysis) or 4-year (long-term
analysis) therapy with adefovir, entecavir or lamivudine from the public payer
perspective in Poland. METHODS: A life-time Markov model based on previously
published analysis was used. States encompassed treatment response (ALT nor-
malization), relapse, complications (compensated/decompensated cirrhosis, hep-
atocellular carcinoma, liver transplantation) and death. Quality-adjusted life years
(QALYs) were the measure of effectiveness. Short-term efficacy assessment was
based on the results of randomized clinical trials (RCTs) corrected for response
duration. Long-term efficacy data for nucleos(t)ide analogues (NAs) were derived
from other published models and RCTs extensions. Utilities and transition proba-
bilities (spontaneous response, relapse, complications, death) were derived from
published literature. Direct medical costs, i.e. costs of drugs and procedures used in
the treatment of CHB and its complications were obtained using a survey con-
ducted among Polish clinicians. In the base case analysis costs and benefits were
discounted at a 5% and 3.5% annual rate, respectively. The robustness of the results
was assessed using one-way, scenario and probabilistic sensitivity analyses.
RESULTS: The short and long-term analysis demonstrated that the use of
PegIFN-2a increased QALYs and life years gained (LYGs) compared to all investi-
gated NAs. In the short-term model PegIFN-2a decreased the costs of complica-
tions treatment and increased the overall costs due to drug acquisition cost. ICERs
for PegIFN-2a vs. lamivudine, adefovir or entecavir amounted to 43,621, 6,600 and
25,166 PLN/QALY, respectively (1€4 PLN). In the long-term model PegIFN-2a was
cost-saving and dominated adefovir, while ICERs vs entecavir and lamivudine
amounted to 5,385 and 73,857 PLN/QALY, respectively. Sensitivity analysis proved
these results to be robust. CONCLUSIONS: Peginterferon alfa-2a is cost-effective
when compared to adefovir, entecavir and lamivudine in Poland.
PIN68
COST- EFFECTIVENESS ANALYSIS OF HUMAN PAPILLOMAVIRUS VACCINATION
PROGRAM IN RUSSIA
Omelyanovsky V, Avxentyeva M, Krysanov I, Ivakhnenko O, Goryaynov S, Tsfasman FM
Research Center for Clinical &Economic Evaluation and Pharmacoeconomics (RC CEE&Ph),
Russian State Medical University, Moscow, Russia
OBJECTIVES:To estimate cost-effectiveness of the vaccination program with quad-
rivalent Human Papillomavirus (HPV 6, 11, 16, 18) recombinant vaccine for the
prevention of cervical intraepithelial neoplasia (CIN) and cervical cancer (CC) in
Russian health care. METHODS: Cost-effectiveness analysis of vaccination pro-
gram vs no vaccination was performed. The previously published model (R. Insinga
et al.) was adjusted for Russia. Rates of CIN and CC were simulated with and
without vaccination in a cohort of girls 12-13 years old. Time-horizon was 24 years.
100% vaccination coverage was assumed. Direct medical costs were estimated.
Outcomes measured were: the cost of averted CIN case and the cost per additional
life-year saved. RESULTS: The cost of introducing HPV vaccination program with
100% coverage of the target audience of 12-13 years old girls is 408,16 mln €
(16,282,34 bln rubles). In the absence of vaccination the costs of providing medical
care to patients with CIN and CC are 160,027 mln € (6, 36 bln rubles). Therefore the
overall costs in a vaccinated cohort were 481,14 mln € (16,285,25 bln rubles). HPV
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